Enlivex terminated its agreement with the Rain Foundation for a private Placement of 66,666,667 ordinary shares payable in RAIN tokens. Investors are affected because the planned issuance will not proceed, and Enlivex will not seek Shareholder approval for the transaction.

Key Highlights

  • The Rain Foundation had elected to use RAIN tokens for the proposed share purchase.
  • Enlivex ended the agreement under its contractual termination rights on September 22, 2026.
  • The planned transaction was subject to shareholder approval before completion.

Enlivex Ltd. (NASDAQ: ENLV) is a biotechnology company. It ended a proposed private placement involving 66,666,667 ordinary shares, removing the planned share issuance from the transaction described with the Rain Foundation. The agreement had been signed on July 27, 2026. The Rain Foundation was set to purchase the shares using RAIN tokens, subject to approval by Enlivex shareholders. Enlivex terminated the securities purchase agreement on September 22, 2026, exercising termination rights provided under the agreement. The company also issued a press release on that date concerning the decision.

Proposed Share Issuance Ends

The private placement will not be completed following the termination. Enlivex will not pursue shareholder approval for the transaction. The proposed buyer was the Rain Foundation, and the securities involved were ordinary shares. Enlivex’s stated action covers both the securities purchase agreement and the private placement contemplated by it.